Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
15.65
+1.50 (10.60%)
At close: Jun 5, 2025, 4:00 PM
15.67
+0.01 (0.10%)
After-hours: Jun 5, 2025, 7:59 PM EDT
Oscar Health Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Oscar Health stock ranges from a low of $12 to a high of $28. The average analyst price target of $18.5 forecasts a 18.21% increase in the stock price over the next year.
Price Target: $18.50 (+18.21%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Oscar Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 4 | 3 | 3 | 3 | 1 |
| Hold | 2 | 2 | 3 | 3 | 3 | 2 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $20 → $16 | Buy → Hold | Downgrades | $20 → $16 | +2.24% | Mar 13, 2025 |
| Jefferies | Jefferies | Sell Initiates $12 | Sell | Initiates | $12 | -23.32% | Dec 10, 2024 |
| B of A Securities | B of A Securities | Hold → Sell Downgrades $21 → $14 | Hold → Sell | Downgrades | $21 → $14 | -13.74% | Nov 6, 2024 |
| UBS | UBS | Hold Initiates $23 | Hold | Initiates | $23 | +46.96% | Oct 7, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $28 | Buy | Reiterates | $28 | +78.91% | Sep 10, 2024 |
Financial Forecast
Revenue This Year
11.55B
from 9.18B
Increased by 25.86%
Revenue Next Year
11.59B
from 11.55B
Increased by 0.34%
EPS This Year
0.70
from 0.10
Increased by 597.68%
EPS Next Year
0.92
from 0.70
Increased by 31.21%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.5B | 13.3B | 14.9B |
| Avg | 11.6B | 11.6B | 13.5B |
| Low | 10.8B | 10.4B | 11.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 36.0% | 15.3% | 28.9% |
| Avg | 25.9% | 0.3% | 16.7% |
| Low | 18.0% | -9.9% | -1.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.92 | 1.18 | 2.36 |
| Avg | 0.70 | 0.92 | 2.01 |
| Low | 0.59 | 0.54 | 1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 824.0% | 68.6% | 158.1% |
| Avg | 597.7% | 31.2% | 119.1% |
| Low | 488.0% | -22.7% | 87.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.